Palvella Therapeutics (NASDAQ:PVLA) Earns Buy Rating from Analysts at Stifel Nicolaus

Stifel Nicolaus assumed coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research note published on Wednesday, Marketbeat reports. The firm issued a buy rating and a $45.00 price target on the stock.

PVLA has been the subject of several other research reports. TD Cowen began coverage on shares of Palvella Therapeutics in a research note on Wednesday, February 5th. They set a “buy” rating and a $44.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $38.00 price target on shares of Palvella Therapeutics in a research report on Tuesday, February 11th. Jones Trading started coverage on Palvella Therapeutics in a report on Tuesday. They issued a “buy” rating and a $45.00 price target for the company. Scotiabank started coverage on Palvella Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 target price for the company. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $39.00 price target on shares of Palvella Therapeutics in a report on Wednesday, February 26th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Palvella Therapeutics has an average rating of “Buy” and an average target price of $43.50.

Palvella Therapeutics Price Performance

Palvella Therapeutics stock opened at $27.93 on Wednesday. The business’s fifty day simple moving average is $19.66. The stock has a market capitalization of $313.40 million, a price-to-earnings ratio of -2.31 and a beta of 0.54. Palvella Therapeutics has a 52-week low of $6.20 and a 52-week high of $29.27.

Institutional Investors Weigh In On Palvella Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new position in shares of Palvella Therapeutics in the 4th quarter valued at $125,000. Toronto Dominion Bank purchased a new stake in Palvella Therapeutics in the 4th quarter valued at about $159,000. Geode Capital Management LLC acquired a new position in Palvella Therapeutics in the fourth quarter valued at about $171,000. Cresset Asset Management LLC purchased a new position in Palvella Therapeutics during the fourth quarter worth about $251,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Palvella Therapeutics during the fourth quarter valued at about $256,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.